GLP-1 receptor agonists

40 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

GLP-1 Receptor Agonists: A Breakthrough in Reducing Atherosclerosis and Cardiovascular Risk Beyond Diabetes and Obesity

GLP-1 receptor agonists significantly reduce atherosclerosis progression, inflammatory biomarkers, and cardiovascular events independent of glycaemic control and obesity status, evidenced by robust preclinical and large-scale clinical data.

Section: CardiologyJul 22, 2026

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

This study evaluates the association between GLP-1 receptor agonists and ischemic optic neuropathy risk compared to SGLT2 and DPP-4 inhibitors, revealing a small but statistically significant increased risk with GLP-1RAs, particularly among

GLP-1 receptor agonists

Latest news

GLP-1 Receptor Agonists: A Breakthrough in Reducing Atherosclerosis and Cardiovascular Risk Beyond Diabetes and Obesity

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

Harnessing Real-World Evidence to Optimize GLP-1-Based Therapies: Insights from a NIDDK Workshop

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study

GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

GLP-1 Weight-Loss and Diabetes Drugs: What Eye Specialists Say About NAION Risk

GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Synthesizing Evidence from Target Trial Emulations and Global Pharmacovigilance

Is Semaglutide Worth the Cost? Evaluating the Economic Reality of GLP-1s for Heart Disease Prevention

Tirzepatide Outperforms Dulaglutide in Cardiovascular Risk Reduction: Insights from Real-World Target-Trial Emulations

Semaglutide Drives Vascular Regeneration: The SEMA-VR CardioLink-15 Trial Reveals a Shift in Progenitor Cell Flux

Synergistic Protection: Combining GLP-1 Receptor Agonists with Lifestyle Habits Slashes Cardiovascular Risk in Type 2 Diabetes

Women Achieve Greater Weight Loss With GLP-1 Receptor Agonists: A Comprehensive Meta-Analysis of Treatment Heterogeneity

Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial

Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes